<DOC>
	<DOCNO>NCT02572284</DOCNO>
	<brief_summary>The purpose study compare effect , good and/or bad , different dos SBRT give prostatectomy . Depending participant enter study , treat either 5 , 6 7 gray ( Gy ) per day radiation . A Gy measure radiation dose . The standard dose 10Gy per day SBRT treatment prostate surgery plan . The researcher want see dose radiation work best least amount side effect . About 4-6 week SBRT , participant prostatectomy .</brief_summary>
	<brief_title>Dose Escalation Study Preoperative SBRT High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologicallyproven prostate adenocarcinoma . Clinical stage ≤T3a base digital rectal exam and/or ≤T3a base MRI ( do ) ; N0Nx ; M0Mx ( AJCC 7th Edition ) Prostatespecific antigen ( PSA ) ≤ 80 ng/ml , obtain within 3 month . Patients belong National Comprehensive Cancer Network ( NCCN ) high recurrence risk group . High risk : Clinical stage T3a , Gleason score = 810 , PSA &gt; 20 ng/mL . Prostate volume : ≤ 80 cc transrectal ultrasound IPSS score ≤15 Zubrod performance status 02 equivalent No prior total prostatectomy cryotherapy prostate . Prior transurethral resection laser ablation permit . No prior radiotherapy prostate lower pelvis No implant hardware material would prohibit appropriate treatment plan treatment delivery , investigator 's opinion No history invasive malignancy ( prostate cancer , nonmetastatic basal squamous skin cancer ) last 5 year No androgen deprivation therapy ( ADT ) prescribe prior radiation therapy Must able gold fiducial marker place prostate , patient already fiducial marker place , must accordance protocol specification Ability understand willingness sign write informed consent document Willingness fill IPSS , RAS , SHIM , EPIC quality life form Age ≥18 year IPSS ( AUA ) score ≤15 Does diagnosis prostate adenocarcinoma Has low risk , low risk , intermediate risk high risk disease define NCCN Has stage N1 M1 ( metastatic ) disease Has PSA great 80 ng/ml obtain great 3 month prior randomization Prostate volume great 80 cc transrectal ultrasound Zubrod performance status 3 great Prior total prostatectomy cryotherapy prostate Prior radiation therapy pelvis Implanted hardware limit treatment planning delivery ( determine investigator ) . Diagnosis invasive malignancy within 5 year ( current prostate cancer nonmetastatic basal squamous skin cancer ) The use androgen deprivation therapy ( ADT ) prior registration radiation Inability gold fiducial marker place prostate , fiducial marker already place , accordance protocol Unwilling inability give inform consent Not willing fill IPSS , RAS , SHIM , EPIC quality life questionnaire IPSS score &gt; 15</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stereotactic Body Radiation Therapy ( SBRT )</keyword>
	<keyword>High Risk Prostate Cancer</keyword>
	<keyword>Preoperative SBRT</keyword>
	<keyword>Prostate Adenocarcinoma</keyword>
	<keyword>Prostatectomy</keyword>
	<keyword>Quality Life</keyword>
</DOC>